Neuralstem (CUR) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Neuralstem (NASDAQ:CUR) from a hold rating to a buy rating in a research report sent to investors on Wednesday.

Shares of Neuralstem stock traded up $0.01 on Wednesday, hitting $0.57. The stock had a trading volume of 66,632 shares, compared to its average volume of 368,033. Neuralstem has a twelve month low of $0.52 and a twelve month high of $3.09.

Neuralstem (NASDAQ:CUR) last posted its earnings results on Wednesday, August 15th. The company reported ($0.04) EPS for the quarter. Neuralstem had a negative net margin of 1,401.80% and a negative return on equity of 75.90%. The firm had revenue of $0.25 million during the quarter.

About Neuralstem

Neuralstem, Inc, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types.

Read More: Stock Symbols and CUSIP Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply